Abstract Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O 6 -methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.
What is Temozolomide?
Temozolomide (TMZ) is an imidazotetrazine derivative of the alkylating agent dacarbazine and a prodrug of the anticancer drug Temodar. 1 The chemical name of TMZ is 3-methyl-4-oxoimidazo [5,1-d] [1, 2, 3, 5] tetrazine-8-carboxamide (Fig. 1) . TMZ is stable at a pH less than 5 but at a pH greater than 7 it is rapidly hydrolyzed to 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC). 2 The lipophilic nature of TMZ permits it to penetrate the bloodbrain-barrier (BBB) allowing it to be administered orally.
Use of Temozolomide (sold as Temodar) to treat brain tumors
TMZ is active against human cancers such as melanomas and astrocytomas. 3e6 It was approved by the US Food and Drug Administration (FDA) for use in the treatment of refractory anaplastic astrocytoma in adults in 1999 and newly diagnosed adult glioblastoma (GBM) patients in 2005. The antitumor effect of TMZ is schedule-dependent with multiple administrations being more effective than a single treatment. In a Phase I clinical trial, the recommended dose of TMZ was 750e1000 mg/m 2 given orally for 5 days per week for 4 weeks. 7 Temodar capsules containing 5e250 mg of TMZ are available for its oral administration to patients and in vials containing 100 mg for those being given TMZ intravenously. Concomitant therapy using both Temodar and radiation improved overall survival of newly diagnosed adult GBM patients relative to those treated with radiation alone (12.1 / 14.6 months median survival). 8 Newly diagnosed GBM patients tend to be given 75 mg/m 2 /day of Temodar for 6 weeks concomitantly with focal radiotherapy (60 Gy) followed by 6 cycles of in which they are given 150 mg/m 2 once daily for 5 days in a row followed by 23 days of no treatment prior to the next cycle. Patients given Temodar iv are injected over a 90 min time period with the same amount that is administered orally.
Mechanism of action of Temozolomide
TMZ is a DNA alkylating agent known to induce cell cycle arrest at G2/M and to eventually lead to apoptosis. 9 At physiologic pH it is converted to the short-lived active compound, MTIC. MTIC is further hydrolyzed to 5-aminoimidazole-4-carboxamide (AIC) and to methylhydrazine. The cytotoxicity of TMZ is mediated by its addition of methyl groups at N 7 and O 6 sites on guanines and the O 3 site on adenines in genomic DNA (Fig. 1) . Alkylation of the O 6 site on guanine leads to the insertion of a thymine instead of a cytosine opposite the methylguanine during subsequent DNA replication, and this can result in cell death.
Temozolomide resistance in natural TMZ resistant GBM cell lines
To identify TMZ resistant GBM cell lines, we conducted literature searches in PubMed/MEDLINE using the terms Temozolomide/TMZ resistant glioblastoma/GBM and acquired Temozolomide/TMZ resistant glioblastoma/GBM. Well-known TMZ sensitive GBM cells are A172, U87, U251, and U373. In contrast, the following GBM cells were reported consistently to be TMZ resistant: LN-18, T98G, and U138. We reported that CCF-STTG1 and U343-MG GBM cells are also TMZ resistant. 22 The LC 50 s (50% cell death concentration) published for TMZ on TMZ sensitive GBM cells vary. For example, Hermisson et al. 16 and Montaldi et al. 30 reported that the LC 50 s of TMZ on U87 GBM cells were 7 mM and 10 mM, while Baer et al. 10 and Ryu et al. 24 noted it as 172 mM and <500 mM. Those reported for the lethality of TMZ on U251 GBM cells also varied: <20 mM, 14 50 mM, 19 <250 mM, 23 <500 mM. 24 The variations in LC 50 may reflect the use of different experimental procedures and cytotoxicity assays (e.g., MTS assay, clonogenic assay). LC 50 s reported for TMZ on TMZ resistant GBM cells also varied. For TMZ on T98G GBM cells LC 50 s were found to range from >250 mM 23 to 1585 mM. 9 The U251 derived U251 nu/nu human glioma cells, which have remarkable transplantability to the nude mouse, behaved analogously to the T98G cells when exposed to TMZ.
14 Interestingly, the trend of the cytotoxic effects of TMZ, as indicated by the LC 50 s, indicates that LC 50 s for TMZ susceptible cells such as U87 or U251 are lower than those for TMZ resistant ones such as T98G. 9, 13, 14, 16, 20, 23, 24, 30 In primary cultured cells, established from GBM patients, CD133 positive cells are more resistant to TMZ than CD133 negative cells. 15 While studying the effects of TMZ on normal human astrocytes (NHA) Agnihotri et al. 23 found that the LC 50 was similar to that for T98G cells (LC 50 : >250 mM) that are not sensitive to TMZ. In another report, 31 immortalized normal human astrocytes which are the most common cell type to cause gliomas had a TMZ LC 50 of 500 mM which is similar to that for TMZ resistant GBM cells. Our recent unpublished finding that TMZ is not cytotoxic to NHA as well as TMZ resistant GBM cells such as T98G and CCF-STTG1 agrees with their results.
Molecular events in natural Temozolomide resistant GBM cells
TMZ is an alkylating agent that acts by methylating DNA adenine and guanine residues (w90%) to form N 3 -methyladenine and N 7 -methylguanine, respectively, and to a lesser extent (5e10%) O 6 -methylguanine (Fig. 1) . The methylated DNA can be repaired by base excision or DNA mismatch repair pathways. While O 6 -methylguanine methyltransferase (MGMT) acts to reverse methylation of the O 6 position of guanine, Bocangel et al. 11 found no correlation between MGMT activity and response to TMZ in their study of 7 human glial tumor cell lines. Their results indicated that a non-functional p53 response to DNA damage was associated more with TMZ resistance than was MGMT activity. They also suggested that p53 mutation status is not the only factor to determine the resistance of cancer cells to TMZ. However, in other studies natural TMZ resistant GBM cells were found to express higher levels of MGMT protein than TMZ sensitive GBM cells. 9,14e16,20e26,30 Expression of MGMT protein was found to correlate inversely with the status of MGMT promoter methylation 32 although MGMT methylated GBM cells such as T98G cells can express MGMT protein and show TMZ resistance. Based on MGMT protein and the MGMT methylated promoter results different labs hypothesized that the response of GBM cells to TMZ might be best predicted by 1) their expression of the MGMT protein, 20 and 2) MGMT promoter methylation status. 32 Agnihotri et al. suggested that the TMZ resistance of T98G GBM cells is due not only to expression of the MGMT protein but to that of alkylpurine-DNA-N-glycosylase (APNG) protein as well. 23 APNG is a base excision repair enzyme that functions in the repair of N 3 -methyladenine and N 7 -methylguanine. A higher expression of nuclear APNG protein correlated with patients having poorer overall survival compared to patients lacking APNG expression. 23 Some TMZ resistant GBM cells do not express the MGMT protein. For example, CCF-STTG1 cells do not express MGMT protein and are resistant to TMZ. 22 Instead of MGMT expression, the CCF-STTG1 cells express more p16INK4A than TMZ sensitive or other TMZ resistant GBM cells. 22 The impact of MGMT promoter methylation on MGMT protein expression has been extensively studied in human GBM patients as well. In studies of GBM patients, MGMT promoter methylation was found to correlate with improved survival when they were treated with alkylating agents like TMZ. 33, 34 The finding that not all GBM patients that had MGMT promoter methylation responded to alkylating agents indicates, in agreement with results described above for the cell studies, that there are multiple molecules involved in TMZ resistance.
In addition to MGMT and APNG protein expression, other proteins and factors have been studied for their effect on TMZ resistance. For example, TMZ resistance is associated with increased breast cancer resistance protein 1 (BCRP1), base excision repair (BER), nicotinamide phosphoribosyl transferase (NAMPT), NAD þ , CD133 expression, and inhibition of apoptosis. 15, 21 Moreover, treatment of U87 and T98G cells with TMZ (200 mM) for 72 h resulted in increased miR-9, 27 and increased expression of connexin 43 induced through activation of the epidermal growth factor receptor (EGFR) and Jun N-terminal kinase-Extracellular Signal Regulated Kinases 1 and 2-activator protein 1 (JNK-ERK1/ 2-AP-1) axis. 28 All of these data indicate that TMZ resistance results from a complex cellular response by the GBM cells.
Gene mutations in natural Temozolomide resistant GBM cells
Possible association between a gene mutation and TMZ resistance in GBM has not been interrogated systemically. Although the best studied gene mutation associated with resistance to TMZ is p53, the results have been mixed. 11, 35 For example, Blough et al. reported that while expression of wild type p53 conveyed more resistance to TMZ than non-functional mutated p53 in cells of established GBM cell lines, it did not in brain tumor initiating cells. 35 In contrast to those results, TMZ sensitive GBM cells (e.g., A172, U87) express wild type of p53 and p53 gene mutations were found in TMZ resistant GBM cells (e.g., LN-18, T98G, U138) as well as TMZ sensitive GBM cells (e.g., U251, U373). 36, 37 Therefore, a mutation in the p53 gene does not appear to be a primary indicator of resistance to TMZ. Interestingly, we observed that all but one (LN-18) of the TMZ resistant GBM cells we have studied have a mutation in the HFE gene 22 which functions in iron homeostasis. Mutations in the HFE gene lead to iron overload in cells expressing it compared to those expressing wild type HFE. There are two major mutations (H63D, C282Y) of the HFE gene. TMZ resistant GBM cells found to express H63D HFE were T98G, U138, and U343, while the only TMZ resistant GBM cells that expressed C282Y HFE were CCF-STTG1. It is unknown whether increased iron or expression of a HFE gene mutant mediates molecular events associated with TMZ resistance. In a recent study of tumor tissues from GBM patients, Nguyen et al. reported that novel MSH6 (mutS homolog 6) mutations influenced the sensitivity of brain tumor initiating cell lines to TMZ regardless of MGMT promoter methylation status. 38 Temozolomide resistance in adapted Temozolomide resistant GBM cell lines Adapted TMZ resistant GBM cells have been generated from both established GBM cell lines and cells isolated from primary tumors treated with TMZ for different times (72 he6 months) ( Table 2) . 19,25,26,29,39e48 Cells from known TMZ sensitive GBM cell lines (e.g., A172, SNB-19, U87, U251, and U373) have been frequently used to generate adapted TMZ resistant GBM cells. In studies, known TMZ resistant GBM cell lines (e.g., LN-18, T98G) were also used. 25 ,44 TMZ resistant cells have been generated by treating them in a Resistance to TMZ of the adapted GBM cells was 2e98 times greater than that of the host cells. Different comparisons of the response to TMZ as measured by the TMZ LC 50 s of adaptive TMZ resistant GBM cells and host cells gave variable results. For example, Auger et al. 41 reported that the LC 50 obtained for TMZ when it was used to treat TMZ-resistant SNB-19 cells was 55e101 mM, while in a study by Zhang et al. 42 it was 280 mM. This difference may reflect the fact that the original responses of the host cells to TMZ differed in the two laboratories: 1.03 mM vs 36 mM. U87 and U251 GBM cells have also been commonly used to generate adaptive TMZ resistant ones. Kohsaka et al. 26 found that the LC 50 for TMZ on acquired TMZ resistant U87 cells, isolated after 3 weeks of exposure to low doses of TMZ, was increased 4 fold, from 40 mM to 150 mM, when measured using a growth inhibition assay, but by 40 fold, from 10 mM to 400 mM, using a clonogenic assay. Similarly, Ujifuku et al. 19 found that the LC 50 for the effect of TMZ on acquired TMZ resistant U251 cells, isolated after a 2 weeks exposure to TMZ, increased at least 6 fold from 50 mM to >300 mM. Some adaptive TMZ resistant GBM cells were generated using known TMZ resistant cell lines such as LN-18. After adaptation by exposure to TMZ for 6 months, the LC 50 of TMZ on adapted resistant LN-18 cells increased 2 fold to w800 mM.
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Mechanisms of Temozolomide resistance in adapted TMZ resistant GBM cells
Adaptive TMZ resistant GBM cells differ from their parent cells at the molecular level. Of particular interest in regard to TMZ resistance are alterations related to known TMZ resistance molecules such as MGMT and DNA repair. Increased MGMT protein expressions were observed in adaptive TMZ resistant SF188, LN-18, U87, U251, and primary tumor derived GBM cells. 25, 26, 39, 40, 46 In addition to an increased expression of MGMT in adaptive TMZ resistant GBM cells, they have been reported to show a decrease in the nuclear factor-Kappa B (NF-kB) pathway modulator Tumor Necrosis Factor-Alpha-Induced Protein 3 (TNFAIP3) and up-regulation of p-p65. 40, 46 Increased expression of Signal Transducer and Activator of Transcription 3 (STAT3) is also found in adaptive TMZ resistant U87 cells. 26 Analyses of MGMT protein expression in adaptive TMZ resistant SNB-19, LNT-229, U251, U343 and U373 cells indicated no change or a decrease in MGMT protein expression. 19,41e44 In adaptive TMZ resistant GBM cells that did not over-express MGMT, expression of other molecules found to participate in TMZ resistance were observed. For example, adaptive TMZ resistant SNB-19 cells showed a loss of gene amplification 41 or down-regulation of MSH6 and upregulation of BER gene NTL1. 42 Down-regulation of DNA mismatch-repair protein was also found in adaptive TMZ resistant LNT-229 cells. 25 The adaptive TMZ resistant U251 cells had an up-regulation of microRNA, 19 upregulation of STAT3/p-STAT3, 42 decreased mitochondrial DNA copy number and remodeling of the mitochondria electron transport chain. 43 Adaptive TMZ resistant GBM cells also have been reported to show activation of JNK, 45 up-regulation of metabolisms of glucose, citrate, and isocitrate, 29 and an increase in histone demethylase KDM5A gene expression. 48 
Temozolomide resistance in animal models
Not many studies have been done to generate TMZ resistant xenograft animal models (Table 3) . 43,49e51 These tumors can be generated by successive injections of TMZ into the flanks of animals bearing TMZ sensitive GBM cell xenografts. When the flank tumors are not inhibited by administration of 120 mg/kg/day of TMZ for 5 days, the tumors are classified as TMZ resistant. The TMZ resistant xenografts had higher mitochondrial complex IIeIV activities and decreased mitochondrial complex I/V activity. 43, 49 Similar molecular events were observed in in vitro studies of adaptive TMZ resistant U251 cells. 43 Like some of the adaptive TMZ resistant GBM cells, strongly induced and prolonged MGMT protein expression was found in TMZ resistant xenografts. 14 IFNs are a family of cytokines that have immunomodulatory, cell differentiation, antiangiogenic, and antiproliferative effects. The effect of IFN-b on TMZ resistant GBM cells may be due to its anti-tumor activity (e.g., cytostatic effects, antitumor immune response). Treatment with IFN-b also activates the p53 pathway that can sensitize TMZ resistant GBM cells to TMZ. Treatment of TMZ resistant tumors with a combination of TMZ and either O 6 -benzylguanine or IFN-b was shown to make the cells more vulnerable to TMZ and synergistic anti-tumor effects than treatment with TMZ alone. 12, 18 The effectiveness of using an oncolytic adenovirus or valproic acid in combination with TMZ has also been studied. 9, 24 Knockdown of an essential base excision repair pathway enzyme apurinic/ apyrimidine endonuclease/redox factor-1 (APE1) also sensitized TMZ resistant T98G cells to TMZ. 30 There are only a few studies of the effects of different drug combinations lacking TMZ on TMZ resistant GBM cells. Results of one such study in which an inhibitor of NAD þ biosynthesis was used in combination with a BER inhibitor indicated that the combination could inhibit TMZ resistant GBM cells. 21 Recent report showed that the combined treatment of monoclonal antibody against EGFR (Nimotuzumab) and mammalian target of rapamycin (mTOR) inhibitor (rapamycin) was more cytotoxic than single treatments including TMZ on patient derived human glioma cells. 31 Like intrinsically TMZ resistant GBM cells, acquired TMZ resistant GBM cells are also vulnerable to O 6 -benzylguanine. 39 Studies of a combination of TMZ and other targeted drugs on acquired TMZ resistant GBM cells indicated that the miR-455-3p inhibitor and TMZ were more cytotoxic than TMZ alone on acquired TMZ resistant U251 cells. 19 The combination of an IkBa inhibitor and TMZ also decreased their survival. 46 Acquired TMZ resistant GBM cells derived from GBM cancer stem cells, were sensitive to treatment with a combination of the histone deacetylase (HDAC) inhibitor (SAHA 1 mM) and TMZ (200 mM). 48 Other drugs analyzed for their effects on acquired TMZ resistant GBM cells are inhibition of microRNA-195, 19 an inhibitor of STAT3 or STAT3 knockdown, 26, 44 an inhibitor of JNK or JNK siRNA, 45 and a glucose analog. 29 In an animal study, a combination of TMZ and a poly ADP ribose polymerase (PARP) inhibitor was found to extend survival of the GBM orthotopic xenografts. 50 In addition to the in vitro and in vivo xenograft studies, the effectiveness of combination treatments comprised of TMZ and a pharmacologic agent (e.g., O6-benzylguanine) on TMZ resistant GBM has been studied in clinical trials. In a phase I clinical trial, patients with recurrent GBM showed a marginal response when treated with a combination of TMZ and dendritic cell vaccination. 52 In a phase II clinical trial, the combination of TMZ and O 6 -BG was ineffective on TMZ resistant GBM patients, but was found to restore TMZ sensitivity in TMZ resistant anaplastic glioma patients. 53 The combination of imatinib and hydroxyurea did not improve recurrent GBM patient survival in phase III clinical study. 54 Conclusions TMZ resistance is a major problem in the treatment of malignant brain tumors. Studies of numerous intrinsic and acquired TMZ resistant GBM cells indicate that TMZ resistance is associated with the expression levels of DNA alkylating proteins and DNA repair enzymes. Results obtained from studies of intrinsic and acquired TMZ resistant GBM cells support the conclusion that TMZ resistance is not mediated by a single molecular event but by multiple ones. Therefore, identification of GBM patients based on the patient's gene/protein profiling data could be beneficial for selecting drugs for their treatment. A potential problem with the use of TMZ to treat GBM patients is that their tumors may acquire TMZ resistance through alteration not only in their expression of DNA alkylating proteins and DNA repair enzymes but in cell signaling pathways as well. While TMZ resistance in GBM has been primarily studied in vitro using different cell models, more studies of TMZ resistance need to be done using patient derived GBM xenograft animal models or tumor tissues of TMZ resistant patients in order to better interrogate potential targets and therapeutic options to pursue for human study.
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